Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic …
W Chen, J Miao, Y Wang, W Xing, X Xu… - Frontiers in …, 2023 - frontiersin.org
Background: According to the 2023 guidelines for treating non-small-cell lung cancer
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
(NSCLC), first-line treatment and recently developed agents for the treatment of epidermal …
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
S Lu, Y Cheng, D Huang, Y Sun, L Wu… - Therapeutic …, 2022 - journals.sagepub.com
Introduction: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers
(NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET …
(NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET …
PEAC: an ultrasensitive and cost-effective MRD detection system in non-small cell lung cancer using plasma specimen
Circulating tumor DNA (ctDNA), a tumor-derived fraction of cell-free DNA (cfDNA), has
emerged as a promising marker in targeted therapy, immunotherapy, and minimal residual …
emerged as a promising marker in targeted therapy, immunotherapy, and minimal residual …
[HTML][HTML] Real-world insights into patients with advanced NSCLC and MET alterations
Objectives To describe characteristics, treatment and outcomes of non-small cell lung
cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET …
cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET …
Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial
Y Cheng, D Huang, J Zhou, C Zhou, Y Sun… - JCO Precision …, 2023 - ascopubs.org
PURPOSE Selpercatinib, a highly selective, potent RET inhibitor with CNS activity,
demonstrated sustained antitumor responses and intracranial activity in patients with RET …
demonstrated sustained antitumor responses and intracranial activity in patients with RET …
[HTML][HTML] Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer
C Li, Y Wang, K Su, Y Liu, L Wang… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background The number of multiple primary lung cancer (MPLC) patients has rapidly
increased in recent years. However, information regarding the etiology of MPLC and …
increased in recent years. However, information regarding the etiology of MPLC and …
A systematic review of health economic evaluation on targeted therapies for first-line treatment of metastatic non-small cell lung cancer (NSCLC): quality evaluation
J Zhao, S Du, Y Zhu, Y Liang, J Lu… - Cancer Management and …, 2020 - Taylor & Francis
Background Evolving practices in non-small cell lung cancer (NSCLC) therapy inevitably
affect health care budgets, especially through the introduction of targeted therapies. This …
affect health care budgets, especially through the introduction of targeted therapies. This …
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center …
Y Gu, J Yu, H Hu, H Zhang, B Cao, L Liang - Thoracic Cancer, 2023 - Wiley Online Library
Background Clinical significance of various subtypes of epidermal growth factor receptor
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
Analysis of the single-cell heterogeneity of adenocarcinoma cell lines and the investigation of intratumor heterogeneity reveals the expression of transmembrane …
P Neuperger, JÁ Balog, L Tiszlavicz, J Furák, N Gémes… - Cancers, 2021 - mdpi.com
Simple Summary Non-small cell lung cancer (NSCLC) is one of the main causes of cancer-
related deaths worldwide. Intratumoral heterogeneity (ITH) is responsible for the majority of …
related deaths worldwide. Intratumoral heterogeneity (ITH) is responsible for the majority of …
Knowledge-guided “Community Network” analysis reveals the functional modules and candidate targets in non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) represents a heterogeneous group of malignancies
that are the leading cause of cancer-related death worldwide. Although many NSCLC …
that are the leading cause of cancer-related death worldwide. Although many NSCLC …